Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Depreciation and Depletion (2016 - 2024)

Historic Depreciation and Depletion for Perspective Therapeutics (CATX) over the last 11 years, with Q4 2024 value amounting to -$1.6 million.

  • Perspective Therapeutics' Depreciation and Depletion fell 25066.37% to -$1.6 million in Q4 2024 from the same period last year, while for Sep 2025 it was -$1.6 million, marking a year-over-year decrease of 23989.41%. This contributed to the annual value of $232000.0 for FY2023, which is 1310.86% down from last year.
  • According to the latest figures from Q4 2024, Perspective Therapeutics' Depreciation and Depletion is -$1.6 million, which was down 25066.37% from $669000.0 recorded in Q3 2024.
  • In the past 5 years, Perspective Therapeutics' Depreciation and Depletion registered a high of $669000.0 during Q3 2024, and its lowest value of -$1.6 million during Q4 2024.
  • Moreover, its 5-year median value for Depreciation and Depletion was $64000.0 (2022), whereas its average is $41526.3.
  • The largest annual percentage gain for Perspective Therapeutics' Depreciation and Depletion in the last 5 years was 28088.24% (2023), contrasted with its biggest fall of 42753.62% (2023).
  • Quarter analysis of 5 years shows Perspective Therapeutics' Depreciation and Depletion stood at $37000.0 in 2020, then crashed by 310.81% to -$78000.0 in 2021, then soared by 276.92% to $138000.0 in 2022, then plummeted by 427.54% to -$452000.0 in 2023, then crashed by 250.66% to -$1.6 million in 2024.
  • Its Depreciation and Depletion was -$1.6 million in Q4 2024, compared to $669000.0 in Q3 2024 and $570000.0 in Q2 2024.